Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Three-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age

NCT04796896 is registered in ClinicalTrials.gov with ModernaTX, Inc. as lead sponsor.

NCT NCT04796896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04796896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Three-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age
Lead sponsor
ModernaTX, Inc.
Phase
Phase 2/3
Overall status
Completed
Start date
March 15, 2021
Completion date
March 15, 2024
Enrollment
11,942 (actual)
Sites
91

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2